

Ref: MHL/Sec&Legal/2025-26/61

October 06, 2025

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended September 30, 2025.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended September 30, 2025. A detailed information update will follow once the Board of Directors approves the financial results for Q2FY26.

Company delivered a strong 23% year-on-year revenue growth at the consolidated level, driven by robust momentum in preventive health check-ups like **TruHealth** and wellness offerings. While the incidence of seasonal illnesses such as Chikungunya, Malaria, Dengue and Viral fever was lower than last year, our performance underscores the strength of our diversified portfolio, resilience against seasonal headwinds, and alignment with the growing customer preference for proactive health and well-being.

Key highlights of Q2FY26 (Consolidated):

1. Revenue growth is approx. 23% on a Y-o-Y basis including revenues from Core Diagnostics, Scientific Pathology (Scientific), Agra and Dr. Ahuja's Pathology & Imaging Center (DAPIC), Dehradun.
2. Post acquisition, Core Diagnostics has progressed from a breakeven position in Q4FY25 to a low single-digit positive margin in Q1FY26 and is now operating at a high single-digit margin in Q2FY26. As highlighted earlier, ongoing improvements in operational efficiency, operating leverage, and synergies are expected to continue driving margin expansion. Additionally, DAPIC (Dehradun) and Scientific (Agra) have consistently outperformed the company's average margin. At the consolidated level, MHL's EBITDA margin remained strong, supported by operating leverage in the organic business and integration synergies at Core Diagnostics, contributing to overall margin enhancement QoQ.
3. The TruHealth Wellness and Specialty segments recorded Y-o-Y growth of ~25% and ~36%, respectively, in Q2FY26.
4. B2C revenues registered a Y-o-Y growth of around 16% on a Y-o-Y basis & B2B revenue growth stood at ~34% on account higher contribution of B2B business in Core Diagnostics.
5. On a consolidated basis, the company is debt free and has net cash surplus of ~INR 55 crores.
6. This quarter, company acquired Dr. RS Patil's Ambika Pathology Laboratory, Kolhapur' ('Ambika Pathology'), effective September 18, 2025. This acquisition strengthens our leadership position in the Kolhapur region and is strategically aimed



at establishing a mini reference laboratory to serve the surrounding 4–5 districts in the Western Maharashtra belt aiming to boost productivity, increase throughput, and reduce turnaround time (TAT).

Key highlights of Q2FY26 (Standalone):

1. Revenues grew by approx. 12% Y-o-Y, driven by an increase in patient and test volumes, a favorable shift in product mix, and improved realizations.
2. EBITDA margins for the current quarter saw a quarter-on-quarter improvement, reflecting resilient business operations and strong operating leverage inherent in the business model. Margins also showed a positive year-on-year trend.

The quarterly business update is on a consolidated basis. The financial results of Q2FY26 are subject to review by Auditors.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh C Kulkarni
Head – Legal & Secretarial

